Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Candida albicans cells with increased cell wall chitin have reduced echinocandin susceptibility in vitro . The aim of this study was to investigate whether C. albicans cells with elevated chitin levels have reduced echinocandin susceptibility in vivo . BALB/c mice were infected with C. albicans cells with normal chitin levels and compared to mice infected with high-chitin cells. Caspofungin therapy was initiated at 24 h postinfection. Mice infected with chitin-normal cells were successfully treated with caspofungin, as indicated by reduced kidney fungal burdens, reduced weight loss, and decreased C. albicans density in kidney lesions. In contrast, mice infected with high-chitin C. albicans cells were less susceptible to caspofungin, as they had higher kidney fungal burdens and greater weight loss during early infection. Cells recovered from mouse kidneys at 24 h postinfection with high-chitin cells had 1.6-fold higher chitin levels than cells from mice infected with chitin-normal cells and maintained a significantly reduced susceptibility to caspofungin when tested in vitro . At 48 h postinfection, caspofungin treatment induced a further increase in chitin content of C. albicans cells harvested from kidneys compared to saline treatment. Some of the recovered clones had acquired, at a low frequency, a point mutation in FKS1 resulting in a S645Y amino acid substitution, a mutation known to confer echinocandin resistance. This occurred even in cells that had not been exposed to caspofungin. Our results suggest that the efficacy of caspofungin against C. albicans was reduced in vivo due to either elevation of chitin levels in the cell wall or acquisition of FKS1 point mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Based on previous research [66–68], to quantify the β-glucan and mannan content within the cell wall, the strains of WT, num11Δ/Δ, and num11Δ/NUM11N were cultivated overnight in 100 milliliters of fresh YPD liquid medium at 30°C and 200 rpm.”
From Mitochondrial anchor protein Num11 is key to pathogenicity of Candida albicans by affecting mitochondrial function and cell wall masking (2025) · cites this paper as [67]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Thus, mutations at these hot spots have been linked to a) impaired enzyme capacity, b) altered cell wall composition, i.e. reduced glucan and increased chit in content, c) increased cell wall thickness and d) impaired filamentation properties, which contribute to a lower growth rate in vitro and in vivo in drosophila and mouse models (31–33).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, mutations at these hot spots have been linked to a) impaired enzyme capacity, b) altered cell wall composition, i.e. reduced glucan and increased chit in content, c) increased cell wall thickness and d) impaired filamentation properties, which contribute to a lower growth rate in vitro and in vivo in drosophila and mouse models (31–33).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Echinocandin resistance in Candida has been linked to loss of fitness for homozygous Fks1p F641 and S645 mutants of C. albicans and Fks2p S663P mutants of C. glabrata (31–33).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, conditions that increase cell wall chitin promote cell survival in the presence of echinocandin76,77, whereas calcineurin inhibitors reduce echinocandin tolerance (measured using MIC assays analyzed after 72 h)68,78.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [77]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Hoffman, C. S., & Winston, F. (1987) · Gene · doi:10.1016/0378-1119(87)90131-4 · Cited by 2,479
Isogenic strain construction and gene mapping in Candida albicans.
Fonzi, W. A., & Irwin, M. Y. (1993) · Genetics · doi:10.1093/genetics/134.3.717 · Cited by 1,687
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“and are effective against Candida isolates which are resistant to other antifungal drugs, such as azoles (16, 51, 54).”
BackgroundConserved Fungal LysM Effector Ecp6 Prevents Chitin-Triggered Immunity in Plants
de Jonge, R., Peter van Esse, H., Kombrink, A., Shinya, T., Desaki, Y., Bours, R., van der Krol, S., Shibuya, N., Joosten, M. H. A. J., & Thomma, B. P. H. J. (2010) · Science · doi:10.1126/science.1190859 · Cited by 777
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · cited 3×
“S645Y is a common mutation in Fks1 HS1 associated with decreased sensitivity to echinocandins (50, 51).”
BackgroundChitin synthesis and fungal pathogenesis
Lenardon, M. D., Munro, C. A., & Gow, N. A. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.05.002 · Cited by 502
Self-citationStimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins
Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000040 · Cited by 445 · cited 10×
“albicans strains with FKS1 hot-spot mutations have increased chitin content compared to wild-type strains (4, 70).”
BackgroundMethodResultSelf-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413
Chitin regulation of immune responses: an old molecule with new roles
Lee, C. G., Da Silva, C. A., Lee, J.-Y., Hartl, D., & Elias, J. A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.10.002 · Cited by 393
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387 · cited 1×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundHsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362 · cited 1×
“A synergistic effect of micafungin with an Hsp90 and with a calcineurin inhibitor was observed in isolates harboring the F641S substitution in Fks1 (64).”
BackgroundA Drug-Sensitive Genetic Network Masks Fungi from the Immune System
Wheeler, R. T., & Fink, G. R. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020035 · Cited by 359 · cited 2×
“albicans stimulates a strong immune response and increases levels of cytokines such as tumor necrosis factor alpha, interleukin-6 (IL-6), IL-10, and gamma interferon (25, 71).”
BackgroundDouglas, C. M., D'Ippolito, J. A., Shei, G. J., Meinz, M., Onishi, J., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A., Bartizal, K., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344 · cited 1×
“An in vitro study showed that an echinocandin-resistant homozygous fks1 point mutant (18) had no further increase in chitin in the presence of caspofungin at a sub-MIC (70).”
BackgroundLaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329 · cited 1×
“The cell wall signaling network, including the PKC, HOG, and Ca2 /calcineurin pathways, activates CHS expression in response to echinocandins, cations, or CFW (11, 22, 33, 35, 47, 70).”
BackgroundThe cell wall architecture of Candida albicans wild‐type cells and cell wall‐defective mutants
Kapteyn, J. C., Hoyer, L. L., Hecht, J. E., Müller, W. H., Andel, A., Verkleij, A. J., Makarow, M., Van Den Ende, H., & Klis, F. M. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01729.x · Cited by 328 · cited 1×
“albicans cell wall buried beneath the outer mannan-rich layer (30, 34).”
BackgroundGarcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323 · cited 2×
“glabrata can also lead to reduced susceptibility to the echinocandins (23).”
BackgroundImmune Recognition of Candida albicans β‐glucan by Dectin‐1
Gow, N. A. R., Netea, M. G., Munro, C. A., Ferwerda, G., Bates, S., Mora‐Montes, H. M., Walker, L., Jansen, T., Jacobs, L., Tsoni, V., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/523110 · Cited by 314 · cited 1×
“albicans stimulates a strong immune response and increases levels of cytokines such as tumor necrosis factor alpha, interleukin-6 (IL-6), IL-10, and gamma interferon (25, 71).”
Self-citationHsp90 Orchestrates Temperature-Dependent Candida albicans Morphogenesis via Ras1-PKA Signaling
Shapiro, R. S., Uppuluri, P., Zaas, A. K., Collins, C., Senn, H., Perfect, J. R., Heitman, J., & Cowen, L. E. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.017 · Cited by 311 · cited 1×
“albicans morphology in a temperature-dependent way via the Ras1-PKA (cyclic AMP-protein kinase A) pathway (63).”
BackgroundDynamic, Morphotype-Specific Candida albicans β-Glucan Exposure during Infection and Drug Treatment
Wheeler, R. T., Kombe, D., Agarwala, S. D., & Fink, G. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000227 · Cited by 309 · cited 1×
“However, during in vivo infection and in response to caspofungin treatment, (1,3)-glucan becomes unmasked in both hyphae and yeast cells, making it more accessible to the -glucan host receptor dectin-1 (71, 72).”
BackgroundMunro, C. A., Selvaggini, S., De Bruijn, I., Walker, L., Lenardon, M. D., Gerssen, B., Milne, S., Brown, A. J. P., & Gow, N. A. R. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05588.x · Cited by 309 · cited 4×
“The cell wall signaling network, including the PKC, HOG, and Ca2 /calcineurin pathways, activates CHS expression in response to echinocandins, cations, or CFW (11, 22, 33, 35, 47, 70).”
BackgroundResultSelf-citationFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Self-citationGarcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250 · cited 1×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundPlaine, A., Walker, L., Da Costa, G., Mora-Montes, H. M., McKinnon, A., Gow, N. A. R., Gaillardin, C., Munro, C. A., & Richard, M. L. (2008) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.08.003 · Cited by 238 · cited 1×
“United Kingdom) as described previously (58).”
Self-citationMacrophages in resistance to candidiasis.
Vázquez-Torres, A., & Balish, E. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.2.170-192.1997 · Cited by 238 · cited 1×
“albicans to survive killing by host macrophages (68).”
BackgroundBalashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225 · cited 9×
“Defects in cell wall (1,3)-glucan due to mutations, such as gas1, are known to activate chitin biosynthesis, and S.”
BackgroundInfluentialStevens, D. A., Espiritu, M., & Parmar, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3407-3411.2004 · Cited by 217 · cited 1×
“concentrations than to lower concentrations of drug (11, 66, 73).”
BackgroundRecognition and Blocking of Innate Immunity Cells by Candida albicans Chitin
Mora-Montes, H. M., Netea, M. G., Ferwerda, G., Lenardon, M. D., Brown, G. D., Mistry, A. R., Kullberg, B. J., O'Callaghan, C. A., Sheth, C. C., Odds, F. C., et al. (2011) · Infection and Immunity · doi:10.1128/iai.01282-10 · Cited by 204 · cited 2×
“The unmasking of (1,3)-glucan may also lead to increased exposure of chitin on the cell surface and thus contribute to the observed elevation in CFW fluorescence intensity of caspofungin-treated high-chitin cells recovered from infected kidneys (45) (Fig.”
BackgroundResultSelf-citationBougnoux, M.-E., Morand, S., & d'Enfert, C. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1290-1297.2002 · Cited by 200 · cited 1×
“Methods for DNA sequence determinations have been described previously (5).”
MethodBreakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196 · cited 2×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundReinoso-Martín, C., Schüller, C., Schuetzer-Muehlbauer, M., & Kuchler, K. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.6.1200-1210.2003 · Cited by 193
Stevens, D. A., Ichinomiya, M., Koshi, Y., & Horiuchi, H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-06 · Cited by 193 · cited 1×
“albicans clinical isolate was associated with an increase in cell wall chitin content (67).”
BackgroundIn Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.760-763.2006 · Cited by 193 · cited 1×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundLaverdière, M., Lalonde, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192 · cited 1×
“The most frequent point mutation resulting in resistance to caspofungin occurs at Ser645 in the HS1 region (36, 50).”
BackgroundLarge-scale production of DNA sequencing templates by microtitre format PCR
Rosenthal, A., Coutelle, O., & Craxton, M. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.1.173 · Cited by 189
Katiyar, S., Pfaller, M., & Edlind, T. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189 · cited 1×
“Some intrinsically echinocandin-resistant fungal species, such as Neurospora crassa, Fusarium solani, Fusarium graminearum, Fusarium verticillioides, and Magnaporthe grisea, have the same echinocandin-resistant Fks1 alleles (32).”
BackgroundPetraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Schaufele, R. L., Francesconi, A., Bacher, J., Avila, N. A., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.12-23.2002 · Cited by 182 · cited 1×
“However, this did not translate into a difference in mortality (52).”
BackgroundChamilos, G., Lewis, R. E., Albert, N., & Kontoyiannis, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00095-07 · Cited by 171 · cited 1×
“glabrata, showed that the occurrence of the paradoxical effect is echinocandin specific and species related (9, 27).”
BackgroundBen-Ami, R., Garcia-Effron, G., Lewis, R. E., Gamarra, S., Leventakos, K., Perlin, D. S., & Kontoyiannis, D. P. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir351 · Cited by 162 · cited 4×
“Furthermore, isolates with fks1 point mutations have thicker walls, elevated chitin levels, and reduced virulence in a murine candidiasis model and in Toll-deficient Drosophila melanogaster (4).”
BackgroundInfluentialPfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.11.5425-5427.2005 · Cited by 161 · cited 1×
“and are effective against Candida isolates which are resistant to other antifungal drugs, such as azoles (16, 51, 54).”
BackgroundFortwendel, J. R., Juvvadi, P. R., Pinchai, N., Perfect, B. Z., Alspaugh, J. A., Perfect, J. R., & Steinbach, W. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01154-08 · Cited by 161 · cited 1×
“The cell wall signaling network, including the PKC, HOG, and Ca2 /calcineurin pathways, activates CHS expression in response to echinocandins, cations, or CFW (11, 22, 33, 35, 47, 70).”
BackgroundProperty Differences among the Four Major Candida albicans Strain Clades
MacCallum, D. M., Castillo, L., Nather, K., Munro, C. A., Brown, A. J. P., Gow, N. A. R., & Odds, F. C. (2009) · Eukaryotic Cell · doi:10.1128/ec.00387-08 · Cited by 153 · cited 1×
“However, clinical isolates are known to vary widely in their ability to cause disease in the systemic candidiasis model (41).”
BackgroundSelf-citationAcquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N., Desnos-Ollivier, M., Garcia-Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, E. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 150 · cited 1×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundMora-Montes, H. M., Bates, S., Netea, M. G., Díaz-Jiménez, D. F., López-Romero, E., Zinker, S., Ponce-Noyola, P., Kullberg, B. J., Brown, A. J. P., Odds, F. C., et al. (2007) · Eukaryotic Cell · doi:10.1128/ec.00350-07 · Cited by 148
Self-citationAttenuated virulence of chitin-deficient mutants of Candida albicans.
Bulawa, C. E., Miller, D. W., Henry, L. K., & Becker, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10570 · Cited by 146 · cited 1×
“For example, the virulence of the Cachs3 chitin synthase mutant with a 70% reduction in chitin content was highly attenuated in a mouse systemic infection model, but the mutant was still able to colonize kidneys (6).”
BackgroundThe yeast cell-wall salvage pathway
Popolo, L., Gualtieri, T., & Ragni, E. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.111.121 · Cited by 142 · cited 1×
“Fungi can remodel damaged cell walls by increasing chitin content to maintain cell wall integrity (47, 59, 69).”
BackgroundMacCallum, D. M., & Odds, F. C. (2005) · Mycoses · doi:10.1111/j.1439-0507.2005.01121.x · Cited by 140
Self-citationKartsonis, N., Killar, J., Mixson, L., Hoe, C.-M., Sable, C., Bartizal, K., & Motyl, M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 138 · cited 1×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundChitin, Chitinases and Chitinase-like Proteins in Allergic Inflammation and Tissue Remodeling
Lee, C. G. (2009) · Yonsei Medical Journal · doi:10.3349/ymj.2009.50.1.22 · Cited by 134 · cited 2×
“Chitin and chitin derivatives can act as pathogenassociated molecular patterns and stimulate innate immune cells (37, 38).”
BackgroundHsp90 orchestrates stress response signaling governing fungal drug resistance
Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000471 · Cited by 130
A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase
Douglas, C. M., Marrinan, J. A., Li, W., & Kurtz, M. (1994) · Journal of Bacteriology · doi:10.1128/jb.176.18.5686-5696.1994 · Cited by 129 · cited 1×
“FKS2 encodes an alternative Fks subunit in Saccharomyces cerevisiae and other fungi (19, 50).”
BackgroundLow Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains
Castanheira, M., Woosley, L. N., Diekema, D. J., Messer, S. A., Jones, R. N., & Pfaller, M. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01711-09 · Cited by 125 · cited 2×
“Our results are consistent with clinical data that indicate that the acquisition of FKS1 mutations in clinical isolates of Candida species is a rare and stochastic event (7).”
BackgroundResultAcquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118 · cited 1×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundMolecular organization of the cell wall of Candida albicans
Klis, F. M., De Groot, P., & Hellingwerf, K. (2001) · Medical Mycology · doi:10.1080/744118876 · Cited by 111 · cited 1×
“albicans cell wall buried beneath the outer mannan-rich layer (30, 34).”
BackgroundMacCallum, D. M., Coste, A., Ischer, F., Jacobsen, M. D., Odds, F. C., & Sanglard, D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-09 · Cited by 98 · cited 1×
“For investigation of early infection stages, a 4-day virulence model was adopted (40, 42); 2 104 CFU per g body weight was injected i.”
MethodSelf-citationGarcı́a-Rodriguez, L. J., Trilla, J. A., Castro, C., Valdivieso, M. H., Durán, A., & Roncero, C. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01835-4 · Cited by 89 · cited 1×
“cerevisiae fks1 null mutants had increased chitin synthase activity and chitin content (17, 24).”
BackgroundDijkgraaf, G. J. P., Abe, M., Ohya, Y., & Bussey, H. (2002) · Yeast · doi:10.1002/yea.866 · Cited by 85 · cited 1×
“cerevisiae fks1 null mutants had increased chitin synthase activity and chitin content (17, 24).”
BackgroundFleischhacker, M., Radecke, C., Schulz, B., & Ruhnke, M. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0411-4 · Cited by 78 · cited 1×
““Paradoxical growth,” or the “Eagle effect,” is a phenomenon by which clinical fungal isolates respond less well in vitro to high drug concentrations than to lower drug concentrations (10, 20, 60, 73).”
BackgroundMacCallum, D. M., Castillo, L., Brown, A. J. P., Gow, N. A. R., & Odds, F. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006420 · Cited by 76 · cited 2×
“For investigation of early infection stages, a 4-day virulence model was adopted (40, 42); 2 104 CFU per g body weight was injected i.”
BackgroundMethodSelf-citationSequence resources at the Candida Genome Database
Arnaud, M. B., Costanzo, M. C., Skrzypek, M. S., Shah, P., Binkley, G., Lane, C. D., Miyasato, S. R., & Sherlock, G. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl899 · Cited by 72 · cited 8×
“Defects in cell wall (1,3)-glucan due to mutations, such as gas1, are known to activate chitin biosynthesis, and S.”
BackgroundInfluentialCota, J. M., Grabinski, J. L., Talbert, R. L., Burgess, D. S., Rogers, P. D., Edlind, T. D., & Wiederhold, N. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01542-07 · Cited by 69 · cited 2×
“The cell wall signaling network, including the PKC, HOG, and Ca2 /calcineurin pathways, activates CHS expression in response to echinocandins, cations, or CFW (11, 22, 33, 35, 47, 70).”
BackgroundEchinocandin pharmacodynamics: review and clinical implications
Pound, M. W., Townsend, M. L., & Drew, R. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq081 · Cited by 67 · cited 1×
““Paradoxical growth,” or the “Eagle effect,” is a phenomenon by which clinical fungal isolates respond less well in vitro to high drug concentrations than to lower drug concentrations (10, 20, 60, 73).”
BackgroundCaspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 63 · cited 1×
“albicans clinical isolates with FKS1 point mutations have been tested in the murine models of systemic candidiasis and showed differences in virulence (4, 74).”
BackgroundKabbara, N., Lacroix, C., Peffault de Latour, R., Socie, G., Ghannoum, M., & Ribaud, P. (2008) · Haematologica · doi:10.3324/haematol.11149 · Cited by 61 · cited 1×
“Although the current incidence of echinocandin resistance is low (53, 55, 56), significant numbers of clinical cases of echinocandin therapy failure have been reported (2, 28, 29, 31, 44, 57, 69).”
BackgroundParadoxical echinocandin activity: a limitedin vitrophenomenon?
Wiederhold, N. P. (2009) · Medical Mycology · doi:10.1080/13693780802428542 · Cited by 54 · cited 2×
““Paradoxical growth,” or the “Eagle effect,” is a phenomenon by which clinical fungal isolates respond less well in vitro to high drug concentrations than to lower drug concentrations (10, 20, 60, 73).”
BackgroundSlater, J. L., Howard, S. J., Sharp, A., Goodwin, J., Gregson, L. M., Alastruey-Izquierdo, A., Arendrup, M. C., Warn, P. A., Perlin, D. S., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01686-10 · Cited by 52 · cited 1×
“Strains selected for in vitro echinocandin resistance that contain an Fks1 Ser645 mutation had very few virulence differences, as measured by fungal burdens (65).”
BackgroundNiimi, K., Monk, B. C., Hirai, A., Hatakenaka, K., Umeyama, T., Lamping, E., Maki, K., Tanabe, K., Kamimura, T., Ikeda, F., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq073 · Cited by 51 · cited 1×
“Previous studies showed that the Km of Fks1 from echinocandin-resistant isolates was not altered but the maximum rate of reaction (Vmax) was reduced (49).”
ResultPhosphorylation regulates polarisation of chitin synthesis inCandida albicans
Lenardon, M. D., Milne, S. A., Mora-Montes, H. M., Kaffarnik, F., Peck, S. C., Brown, A. J. P., Munro, C. A., & Gow, N. A. R. (2010) · Journal of Cell Science · doi:10.1242/jcs.060210 · Cited by 45
Self-citationMesser, S. A., Jones, R. N., Moet, G. J., Kirby, J. T., & Castanheira, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00328-10 · Cited by 39
Exposure to caspofungin activates Cap and Hog pathways in Candida albicans
Kelly, J., Rowan, R., Mccann, M., & Kavanagh, K. (2009) · Medical Mycology · doi:10.3109/13693780802552606 · Cited by 36 · cited 2×
“5 mM hydrogen peroxide resulted in decreased sensitivity to caspofungin (33).”
BackgroundDevelopment and use of complex probes for DNA fingerprinting the infectious fungi
Lockhart, S. R., Pujol, C., Joly, S., & Soll, D. R. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.1.8 · Cited by 28
Jacobsen, M. D., Whyte, J. A., & Odds, F. C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-06 · Cited by 27 · cited 1×
“glabrata, showed that the occurrence of the paradoxical effect is echinocandin specific and species related (9, 27).”
BackgroundSelf-citationCastillo, L., MacCallum, D. M., Brown, A. J. P., Gow, N. A. R., & Odds, F. C. (2010) · Infection and Immunity · doi:10.1128/iai.01004-10 · Cited by 21
Self-citationIn Vitro Susceptibilities to Caspofungin and Micafungin of Clinical Isolates of Candida Species
Choi, H. W., Shin, J. H., Lee, J. S., Cho, D., Shin, M. G., Suh, S., & Ryang, D. W. (2006) · Annals of Laboratory Medicine · doi:10.3343/kjlm.2006.26.4.275 · Cited by 6 · cited 1×
““Paradoxical growth,” or the “Eagle effect,” is a phenomenon by which clinical fungal isolates respond less well in vitro to high drug concentrations than to lower drug concentrations (10, 20, 60, 73).”
Background
Research works printed but not linked: 2
- 10.1080/mmy.39.1.1.8-0 · DOI · Paper page
- 10.1128/mmbr.61.2.170-192.1997 · doi:10.1128/mmbr.61.2.170-192.1997 · Paper page
Cited by
The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species
Garcia-Rubio, R., de Oliveira, H. C., Rivera, J., & Trevijano-Contador, N. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02993 · Cited by 917
“Strains with elevated levels of chitin in its cell wall also show an echinocandin resistant profile as revealed in a systematic in vivo infection model of candidiasis (Lee et al., 2012).”
BackgroundAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“albicans infection (Lee et al. 2012).”
BackgroundEchinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
“mutant strains with elevated chitin content have been shown to be less susceptible to echinocandins in vitro [30, 31, 35] and in an animal model [36].”
Metadata
- Authors
- Lee, K. K., MacCallum, D. M., Jacobsen, M. D., Walker, L. A., Odds, F. C., Gow, N. A. R., & Munro, C. A.
- Affiliations
- University of Aberdeen (GB)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-01
- Volume
- 56
- Issue
- 1
- Pages
- 208-217
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3256049
- OpenAlex
- W2127997803
- Cited by
- 209
- References
- 77
- Citations by year
- 2026: 11 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 9 · 2021: 18 · 2020: 20 · 2019: 16 · 2018: 14 · 2017: 15 · 2016: 12 · 2015: 15 · 2014: 19 · 2013: 16 · 2012: 12
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (086827, 080088)
- University of Aberdeen
- Chinese Academy of Agricultural Sciences
- Biotechnology and Biological Sciences Research Council (BB/F00513X/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- Candida albicans, echinocandin resistance, caspofungin, FKS1 mutations, antifungal susceptibility, kidney fungal burden, fungal virulence
- MeSH terms
- Caspofungin, Animals, Antifungal Agents, Candida albicans, Candidiasis, Cell Wall, Chitin, DNA Mutational Analysis, Female, Fungal Proteins, Glucosyltransferases, Kidney, Mice, Inbred BALB C, Microbial Sensitivity Tests, Microscopy, Fluorescence, Mutation, Survival Rate, Amino Acid Substitution, Drug Resistance, Fungal, Mice, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.